Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.